hp Pharmaceuticals will pay $ 500 m to acquire pharmaceutical company Exonics and extend its agreement with hp Therapeutics for the treatment of Duchenne muscular dystrophy ( DMD ) and myotonic dystrophy # 1 ( DM1 ) . Boston - based Vertex has secured an exclusive discovery and development deal with CRISPR ##® , which it will use along with resources from Exonics to develop independent DMD products and continue research on DM1 drugs .
Vertex Pharmaceuticals will pay $420m to acquire biotechnology company Exonics and extend its agreement with CRISPR Therapeutics for the treatment of Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1). Boston-based Vertex has secured an exclusive discovery and development deal with CRISPR Therapeutics, which it will use along with resources from Exonics to develop independent DMD products and continue research on DM1 treatments.